🟢 HCW Biologics is trading 5.7% up in pre-market with no clear company-specific catalyst

HCW Biologics is trading at $1.30, up 5.7% in pre-market, with no clear company-specific catalyst identified.

• That compares with $1.23 at the October 15 close.
• The latest company announcement found was October 9 FDA guidance for preparing an IND application for its solid-tumor candidate; filing remains targeted for the first half of 2027. This does not establish the reason for the October 16 move.
• Major-index pre-market moves were modest, offering no clear broad-market explanation; volume was unavailable.